Susquehanna International Group, LLP Editas Medicine, Inc. Put Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Put Options

29 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$3.39 - $5.96 $39,663 - $69,732	11,700 Added 8.39%	151,100 $515,000
Q2 2024 Aug 15, 2024	SELL	$4.67 - $7.28 $357,255 - $556,920	-76,500 Reduced 35.43%	139,400 $650,000
Q1 2024 May 07, 2024	BUY	$7.03 - $11.07 $225,663 - $355,347	32,100 Added 17.46%	215,900 $1.6 Million
Q4 2023 Feb 14, 2024	BUY	$6.25 - $11.11 $796,250 - $1.42 Million	127,400 Added 225.89%	183,800 $1.86 Million
Q3 2023 Nov 14, 2023	BUY	$6.92 - $9.31 $2,076 - $2,793	300 Added 0.53%	56,400 $439,000
Q2 2023 Aug 11, 2023	SELL	$6.36 - $11.47 $85,224 - $153,698	-13,400 Reduced 19.28%	56,100 $461,000
Q1 2023 May 16, 2023	SELL	$7.03 - $11.53 $812,668 - $1.33 Million	-115,600 Reduced 62.45%	69,500 $503,000
Q4 2022 Feb 14, 2023	SELL	$8.32 - $13.21 $486,720 - $772,785	-58,500 Reduced 24.01%	185,100 $1.64 Million
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $291,840 - $466,080	24,000 Added 10.93%	243,600 $2.98 Million
Q2 2022 Aug 15, 2022	SELL	$9.99 - $21.35 $398,601 - $851,865	-39,900 Reduced 15.38%	219,600 $2.6 Million
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $1.18 Million - $2.32 Million	-84,000 Reduced 24.45%	259,500 $4.94 Million
Q4 2021 Feb 14, 2022	SELL	$26.55 - $40.57 $16.3 Million - $24.9 Million	-614,500 Reduced 64.14%	343,500 $9.12 Million
Q3 2021 Nov 15, 2021	BUY	$39.27 - $72.94 $20.6 Million - $38.2 Million	524,400 Added 120.94%	958,000 $39.4 Million
Q2 2021 Aug 11, 2021	BUY	$31.29 - $56.64 $2.41 Million - $4.37 Million	77,100 Added 21.63%	433,600 $24.6 Million
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $3.46 Million - $7.9 Million	87,200 Added 32.38%	356,500 $15 Million
Q4 2020 Feb 16, 2021	BUY	$27.07 - $84.35 $3.25 Million - $10.1 Million	120,100 Added 80.5%	269,300 $18.9 Million
Q3 2020 Nov 16, 2020	BUY	$28.06 - $37.16 $1.64 Million - $2.17 Million	58,400 Added 64.32%	149,200 $4.19 Million
Q2 2020 Aug 14, 2020	SELL	$18.5 - $34.34 $882,450 - $1.64 Million	-47,700 Reduced 34.44%	90,800 $2.69 Million
Q1 2020 May 15, 2020	SELL	$14.88 - $32.78 $3.62 Million - $7.99 Million	-243,600 Reduced 63.75%	138,500 $2.75 Million
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $841,967 - $1.41 Million	43,200 Added 12.75%	382,100 $11.3 Million
Q3 2019 Nov 14, 2019	SELL	$22.49 - $26.81 $391,326 - $466,494	-17,400 Reduced 4.88%	338,900 $7.71 Million
Q2 2019 Aug 14, 2019	SELL	$20.48 - $27.76 $1.07 Million - $1.45 Million	-52,300 Reduced 12.8%	356,300 $8.82 Million
Q1 2019 May 15, 2019	BUY	$19.43 - $26.41 $1.12 Million - $1.52 Million	57,500 Added 16.38%	408,600 $9.99 Million
Q4 2018 Feb 14, 2019	SELL	$18.19 - $31.79 $1.62 Million - $2.83 Million	-88,900 Reduced 20.2%	351,100 $7.99 Million
Q3 2018 Nov 14, 2018	SELL	$27.65 - $38.39 $218,435 - $303,281	-7,900 Reduced 1.76%	440,000 $14 Million
Q2 2018 Aug 14, 2018	SELL	$31.4 - $41.01 $8.71 Million - $11.4 Million	-277,400 Reduced 38.25%	447,900 $16 Million
Q1 2018 May 15, 2018	BUY	$29.84 - $44.08 $5.92 Million - $8.75 Million	198,400 Added 37.65%	725,300 $24 Million
Q4 2017 Feb 14, 2018	BUY	$21.89 - $31.34 $4.91 Million - $7.03 Million	224,400 Added 74.18%	526,900 $16.2 Million
Q3 2017 Nov 14, 2017	BUY	$15.81 - $24.01 $4.78 Million - $7.26 Million	302,500	302,500 $7.26 Million

Others Institutions Holding EDIT

# of Institutions

248

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

Black Rock Inc. New York, NY

7.78M
Shares

$20.7 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

6.68M
Shares

$17.8 Million
0.0% of portfolio
Deep Track Capital, LP Greenwich, CT

4.9M
Shares

$13 Million
0.62% of portfolio
Israel Englander Millennium Management LLC | New York, Ny

3.35M
Shares

$8.91 Million
0.01% of portfolio
State Street Corp Boston, MA

2.46M
Shares

$6.55 Million
0.0% of portfolio

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $183M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account